3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Praxis Precision Medicines Inc

Praxis Precision Medicines (PRAX) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Praxis Precision Medicines Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

Ulixacaltamide review and launch

  • FDA late-cycle meeting completed; discussions focused largely on label wording, with management describing strong alignment and expecting approval by January, subject to FDA decisions.

  • Management expects a broad adult essential tremor label, with no efficacy differences identified across subgroups; alternative titration is likely to be included to help address discontinuations.

  • Launch preparations are underway; shipment can begin immediately after approval if no scheduling is required, while a scheduling process could delay shipment by a few months.

  • Management views no scheduling as preferable for supply-chain simplicity; if scheduled, a rating of four or five was described as the maximum possibility.

  • Potential post-approval studies remain under discussion; management suggested any requirements might involve preclinical work or special populations, with no expected major impact.

Relutrigine review

  • Late-cycle discussions involved information requests and questions requiring resolution; there were no pending information requests at the time of the conference.

  • Review was characterized as somewhat behind ulixacaltamide, with more meaningful open questions and less certainty; management said the interactions had not changed launch plans and continued to expect approval.

  • The PDUFA date was identified as December 27; management said the review questions were being addressed ahead of a decision.

EMERALD and pipeline updates

  • EMERALD reached last patient, last visit; data cleaning and quality checks are ongoing, and management plans to report results during the NDA review period after completing detailed data QC.

  • Enrollment pace was similar across the first and second halves, leaving a substantial open-label cohort with completed visits at readout; management expects this to add context for prescribers.

  • EMERALD is etiologically driven; SCN1A patients account for a low single-digit percentage of enrollment, which management said could not change the study outcome.

  • Management described a strong long-term disease and seizure-control signal and sees EMERALD as part of the planned evidence package for SCN2A and SCN8A, subject to FDA review comments.

  • EMBRAVE3 alone has a very high likelihood of serving as the elsunersen NDA study; an FDA Type B meeting was completed, with submission timing to be updated later that week.

  • POWER2 is underway; POWER3 is planned to start next year, following additional expert input on study design.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Praxis Precision Medicines